PBL InterferonSource collaborates with AVANZA

PBL InterferonSource (PBL) and AVANZA Laboratories announced collaboration between their two organizations that will focus on enhancing their ability to service the biopharmaceutical industry.

The role and regulation of protein biomarkers in diseases is a major focus area, particularly in cancer, autoimmune disease and inflammatory disease. Understanding the role of biomarkers in various disease states is becoming increasingly important as drug development moves towards the use of biologics for therapeutics. The joint venture will enable the companies to provide a broader offering for their customers that will include specialized assay development, technology collaborations, and innovative platform applications which will support protein biomarker research and cytokine drug development.

PBL InterferonSource CEO Robert Pestka said: “We have a deep understanding of interferons and cytokines as therapeutics and potential biomarkers. It’s exciting to bring AVANZA’s complementary service offerings together with our technical expertise to serve the drug development industry.”

AVANZA Laboratories’ executive vice president Ira DuBey commented: “Scientists are just beginning to unravel the roles that interferons and cytokines have in various diseases. We believe our partnership with PBL will allow us to provide relevant data faster and increase the efficiency of drug development, saving time and money.”